PUBLICATIONS

• Tappenden P, Wang Y, Sharrack B, Burman J, Kazmi M, Saccardi R, Bermejo I, Harvey R, et al. Evaluating the clinical effectiveness of autologous haematopoietic stem cell transplantation versus disease-modifying therapy in multiple sclerosis using a matching-adjusted indirect comparison: an exploratory study from the Autoimmune Diseases Working Party (ADWP) of the European Society of Bone and Marrow Transplantation (EBMT), Bone Marrow Transplantation, 2019 doi:10.1038/s41409-019-0747-2 [LINK]

• Charokopou M, Harvey R, Srivastava K et al. Relative performance of brivaracetam as adjunctive treatment of focal seizures in adults: a network meta-analysis, Current Medical Research and Opinion, 2019, 35(8):1345-54 [LINK]

Harvey R. Second-line treatments for advanced gastric cancer: A network meta-analysis of overall survival using parametric modelling methods, Oncology and Therapy, 2017, 5(1):53-67 [LINK]

Harvey R, Shields G, James A. A systematic review and network meta-analysis to assess positive and negative symptoms in early-onset schizophrenia, CNS Drugs, 2016, 30(1):27-39 [LINK]

• Morrell C, Sutcliffe P, Booth A, Stevens J, Scope A, Stevenson M, Harvey R, et al. A systematic review, evidence synthesis and meta-analysis of quantitative and qualitative studies evaluating the clinical effectiveness, the cost-effectiveness, safety and acceptability of interventions to prevent postnatal depression. Health Technology Assessment, 2016, 20(37):1-414 [LINK]

• Squires H, Stevenson M, Simpson E, Harvey R, et al. Trastuzumab emtansine for treating HER2-positive, unresectable, locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane: An Evidence Review Group perspective of a NICE Single Technology Appraisal, PharmacoEconomics, 2016, 24(7):673-80 [LINK]

• Archer R, Tappenden P, Ren S, Martyn-St James, Harvey R, et al. Infliximab, adalimumab and golimumab for treatment of moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness, systematic review and economic model, Health Technology Assessment, 2016, 20(39):1-326 [LINK]

• Tappenden P, Ren S, Archer R, Harvey R, et al. A model-based economic evaluation of biologic and non-biologic options for the treatment of adults with moderately-to-severely active ulcerative colitis after the failure of conventions therapy, PharmacoEconomics, 2016, 34(10):1023-38 [LINK]

• Stevens J, Khunti K, Harvey R, et al. Preventing the progression to type 2 diabetes mellitus in adults at high risk: A systematic review and network meta-analysis of lifestyle, pharmacological and surgical interventions, Diabetes Research and Clinical Practice, 2015, 107(3):320-31 [LINK]

• Brown J, Wiggins J, Dong H, Harvey R, et al. The hard Test Your Memory. Evaluation of a short cognitive test to detect mild Alzheimer’s disease and amnestic mild cognitive impairment, International Journal of Geriatric Psychiatry, 2014, 29(3):272-80 [LINK]

• Nelson A, Harvey R, Parker R, et al. Repeat prostate biopsy strategies after initial negative biopsy: meta-regression comparing cancer detection of transperineal, transrectal saturation and MRI-guided biopsy, PLoS ONE, 2013, 8(2):e57480 [LINK]

• Sastry P, Rivinius R, Harvey R, et al. The influence of endoscopic vein harvesting on outcomes after coronary bypass grafting: A meta-analysis of 267,525 patients, European Journal of Cardio-Thoracic Surgery, 2013, 44(6):980-89 [LINK]

• Alrawi Y, Parker R, Harvey R, et al. Predictors of early mortality among hospitalized nursing home residents, QJM: An International Journal of Medicine; 106(1), 2013 [LINK]

Harvey R. Treatment of post-menopausal advanced breast cancer: Network meta-analysis using second-order fractional polynomial models, Value in Health, Volume 21, S18 [LINK]

• Cranmer H, Harvey R. Podium Presentation at ISPOR 20th Annual European Congress (2017): Network meta-analysis of hazard ratios vs. fractional polynomials approach in a cost-effectiveness analysis considering advanced gastric cancer, Value in Health, Volume 20, Issue 9, A401 [LINK]

Harvey R, Cranmer H, Tolley K. Estimation of health-related quality of life (HRQoL) in cancer patients utilising a time-to-death analysis, Value in Health, Volume 20, Issue 9, A767 [LINK]

• Charokopou M, Harvey R, Srivastava K, et al. Applying the accepted techniques of indirect treatment comparison to meet payer needs for brivaracetam versus adjunctive anti-epileptic medications for the treatment of focal seizures in adult patients. Do they reflect the need for individualised patient care in heterogeneous populations in epilepsy? Value in Health, Volume 19, Issue 7, A359 [LINK]

Harvey B, Stradwick S, Brereton N, et al. Comparative effectiveness of peak and trough effects of bimatoprost 0.03%/timolol 0.5% preservative-free fixed combination for the treatment of open-angle glaucoma and ocular hypertension, Value in Health, Volume 16, Issue 7, A502 [LINK]

• Lee D, Harvey B, Gaudin A, et al. An exploratory analysis of the association between EORTC-QLQ C30 domains and progression free/overall survival in advanced melanoma after 12 weeks of treatment on ipilimumab compared to gp100 in a phase III clinical trial, Value in Health, Volume 16, Issue 7, A422. [LINK]